Race Oncology Limited (ASX:RAC) is an Australian pharmaceutical company focused on the development of its key drug, Zantrene, which is currently being studied for pre-clinical and clinical efficacy in several cancer indications. Zantrene is...

Race Develops Improved IV Formulation of Zantrene

09/28/22

Race Develops Improved IV Formulation of Zantrene

To discuss or comment on this announcement please visit our Investor Hub....

Race Initiates FTO & ALKBH5 Drug Discovery Program

09/27/22

Race Initiates FTO & ALKBH5 Drug Discovery Program

To discuss or comment on this announcement please visit our Investor Hub....

Race Oncology 2022 Annual Report

08/26/22

Race Oncology 2022 Annual Report

...

Race Oncology June 2022 Quarterly Investor Briefing

07/28/22

Race Oncology June 2022 Quarterly Investor Briefing

Race Oncology CEO Phillip Lynch and CSO Dr Daniel Tillett present Race’s June 2022 Quarterly Investor Briefing followed by a Q&A session....

June 2022 Quarterly Activity Report

07/22/22

June 2022 Quarterly Activity Report

...